Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Teva Pharmaceutical Industries and Polpharma Biologics are advancing PB018, a proposed Ocrevus biosimilar for multiple sclerosis, under a global licensing agreement covering major pharmaceutical markets. Representative image.
Pharma & Biotech

Teva wants a slice of Roche’s CHF 7bn Ocrevus franchise, but PB018 still has a long road ahead

Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.

Read More
Rani Therapeutics and PegBio are evaluating the RaniPill platform for oral delivery of obesity and metabolic disease therapies now administered by injection. Representative image.
Pharma & Biotech

How Rani Therapeutics could convert PegBio’s injectable metabolic drugs into oral therapies

Rani Therapeutics Holdings, Inc. and PegBio Co., Ltd. have formed a research and development collaboration to evaluate whether several injectable obesity and metabolic disease candidates can be delivered through Rani Therapeutics’ swallowable RaniPill platform. The partners plan to screen oral formulations, complete preclinical development and select the most promising programmes for possible advancement into human

Read More
Arialys Therapeutics’ ART5803 has received FDA Fast Track designation as the company advances a Phase 2 precision therapy for anti-NMDA receptor encephalitis. Representative image.
Pharma & Biotech

ART5803 gets FDA Fast Track status, but the real test for Arialys Therapeutics begins in Phase 2

FDA Fast Track status advances Arialys Therapeutics’ ART5803 as Phase 2 trials test a precision approach to anti-NMDA receptor encephalitis.

Read More
Leads Biolabs secures China priority review for opamtistomig in advanced extrapulmonary neuroendocrine carcinoma, advancing its bispecific cancer immunotherapy toward approval. Representative image.
Pharma & Biotech

Leads Biolabs wins China priority review for opamtistomig in advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. has secured priority review in China for the biologics licence application covering opamtistomig as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma after at least two previous systemic treatment lines. The July 10, 2026 decision moves the Hong Kong-listed biotechnology company, traded under stock code 9887, closer to a possible first

Read More
Hansoh Pharmaceutical Group’s Ris-Rez delivers an overall survival benefit in the Phase 3 ARTEMIS-008 trial for advanced small-cell lung cancer. Representative image.
Pharma & Biotech

Hansoh Pharma’s Ris-Rez improves survival in Phase 3 small-cell lung cancer trial

Hansoh Pharmaceutical Group Co., Ltd. has reported that risvutatug rezetecan, also known as Ris-Rez or HS-20093, significantly improved overall survival in the pivotal Phase 3 ARTEMIS-008 trial involving Chinese patients with advanced or relapsed small-cell lung cancer following platinum-based treatment. The B7-H3-directed antibody-drug conjugate was compared with topotecan and also produced a consistent benefit in

Read More
LEO Pharma’s TRAPEDS-1 trial evaluated the pharmacokinetics and long-term safety of tralokinumab in children with moderate-to-severe atopic dermatitis. Representative image.
Pharma & Biotech

LEO Pharma reports long-term pediatric tralokinumab safety findings from TRAPEDS-1

LEO Pharma’s TRAPEDS-1 data support pediatric tralokinumab development, but the small trial leaves efficacy and approval questions open.

Read More
FDA approval of Keytruda and Keytruda Qlex with Padcev expands perioperative treatment options for adults with muscle-invasive bladder cancer. Representative image.
Pharma & Biotech

Can Keytruda plus Padcev replace cisplatin chemotherapy before bladder cancer surgery?

FDA approval moves Keytruda and Padcev into perioperative MIBC regardless of cisplatin eligibility, intensifying the contest for standard care.

Read More
Precisio Biotix’s ClyO therapy is being evaluated for a chronic multidrug-resistant prosthetic joint infection, highlighting the search for new treatments against persistent implant-related bacterial infections. Representative image.
Pharma & Biotech

Precisio Biotix begins extended ClyO treatment for chronic prosthetic joint infection

Precisio Biotix reports early ClyO use in chronic prosthetic joint infection, highlighting its promise, evidence limits and regulatory hurdles.

Read More
FDA approval of Padcev plus Keytruda expands perioperative treatment options for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. Representative image.
Pharma & Biotech

Pfizer and Astellas secure wider FDA label for Padcev plus Keytruda in muscle-invasive bladder cancer

FDA expands Padcev plus Keytruda to adults with muscle-invasive bladder cancer regardless of cisplatin eligibility, reshaping perioperative care.

Read More
Glaucoma eye examination in progress as Bausch + Lomb discontinues BL1107 eye drops after the Phase 2 trial missed key visual function endpoints. Representative image.
Pharma & Biotech

Why Bausch + Lomb stopped its BL1107 neuroprotective glaucoma eye-drop program

Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.

Read More